FYERS
Home
/
Stocks
/
Results
/
Concord Biotech Results

Concord Biotech Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
-11%7%-12%
-2%3%-30%
--14%-15%
20%19%19%14%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
LUPIN
MANKIND
DRREDDY
AUROPHARMA
CONCORDBIO
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,916₹463791 Cr38.3412.0762.82₹11479 Cr
9,250₹245081 Cr83.7934.04128.41₹2568 Cr
4,905.5₹190351 Cr87.2816.7297.06₹2163 Cr
1,143₹114833 Cr25.449.4262.53₹5040 Cr
1,394.7₹114163 Cr33.879.7757.87₹3879 Cr
1,868.5₹100660 Cr92.066.829.25₹889 Cr
2,132₹98431 Cr17.830.95154.36₹5333 Cr
2,368.8₹98305 Cr48.1313.7571.08₹1913 Cr
1,155₹96906 Cr30.075.3263.99₹4196 Cr
1,637.3₹95300 Cr25.6717.9596.84₹3505 Cr
1,450₹15090 Cr54.85.5933.47₹261 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022
₹257 Cr₹326 Cr₹278 Cr₹247 Cr₹204 Cr₹430 Cr₹244 Cr₹310 Cr₹216 Cr₹319 Cr₹241 Cr₹262 Cr₹195 Cr₹273 Cr₹241 Cr₹159 Cr₹181 Cr
₹13 Cr₹15 Cr₹10 Cr₹13 Cr₹14 Cr₹9 Cr₹15 Cr₹10 Cr₹10 Cr₹11 Cr₹8 Cr₹8 Cr₹7 Cr₹12 Cr₹9 Cr₹6 Cr₹8 Cr
₹270 Cr₹341 Cr₹288 Cr₹260 Cr₹218 Cr₹439 Cr₹259 Cr₹320 Cr₹226 Cr₹330 Cr₹249 Cr₹270 Cr₹201 Cr₹285 Cr₹250 Cr₹165 Cr₹189 Cr
₹193 Cr₹227 Cr₹198 Cr₹177 Cr₹160 Cr₹254 Cr₹160 Cr₹187 Cr₹148 Cr₹198 Cr₹148 Cr₹156 Cr₹136 Cr₹158 Cr₹143 Cr₹133 Cr₹130 Cr
₹95 Cr₹134 Cr₹109 Cr₹102 Cr₹75 Cr₹200 Cr₹113 Cr₹147 Cr₹92 Cr₹145 Cr₹114 Cr₹127 Cr₹79 Cr₹141 Cr₹121 Cr₹44 Cr₹72 Cr
₹4 L₹8 L₹8 L₹6 L₹6 L₹10 L₹10 L₹10 L₹24 L₹46 L₹50 L₹84 L₹75 L₹1 Cr₹91 L₹1 Cr₹1 Cr
₹77 Cr₹114 Cr₹87 Cr₹83 Cr₹57 Cr₹185 Cr₹99 Cr₹133 Cr₹78 Cr₹131 Cr₹100 Cr₹113 Cr₹65 Cr₹126 Cr₹106 Cr₹30 Cr₹58 Cr
₹56 Cr₹89 Cr₹64 Cr₹61 Cr₹43 Cr₹142 Cr₹74 Cr₹99 Cr₹58 Cr₹97 Cr₹75 Cr₹84 Cr₹48 Cr₹94 Cr₹79 Cr₹22 Cr₹43 Cr

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
———————
₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr₹10 Cr
₹2007 Cr₹1802 Cr₹1516 Cr₹1280 Cr₹1094 Cr₹990 Cr₹761 Cr
₹2007 Cr₹1802 Cr₹1516 Cr₹1280 Cr₹1094 Cr₹990 Cr₹761 Cr
₹2017 Cr₹1813 Cr₹1527 Cr₹1290 Cr₹1103 Cr₹999 Cr₹770 Cr
-₹2 Cr₹0₹0₹0₹0₹0₹0
₹0₹0₹0₹6 Cr₹31 Cr₹56 Cr₹36 Cr
₹42 Cr₹34 Cr₹28 Cr₹23 Cr₹21 Cr₹17 Cr₹15 Cr
₹1 Cr₹63 L₹2 Cr₹16 L₹31 L₹2 Cr₹3 Cr
₹4 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr
₹48 Cr₹37 Cr₹32 Cr₹32 Cr₹54 Cr₹77 Cr₹55 Cr
———————
₹102 Cr₹113 Cr₹94 Cr₹94 Cr₹83 Cr₹46 Cr₹71 Cr
₹56 Cr₹55 Cr₹38 Cr₹62 Cr₹66 Cr₹54 Cr₹42 Cr
₹0₹38 L₹0₹0₹4 Cr₹5 Cr₹0
₹11 Cr₹16 Cr₹9 Cr₹36 Cr₹191 Cr₹131 Cr₹110 Cr
₹169 Cr₹184 Cr₹142 Cr₹192 Cr₹344 Cr₹236 Cr₹223 Cr
₹2232 Cr₹2034 Cr₹1701 Cr₹1514 Cr₹1502 Cr₹1313 Cr₹1049 Cr
₹4 Cr₹4 Cr₹14 Cr₹14 Cr₹13 Cr₹4 Cr₹4 Cr
₹0₹38 L₹6 Cr₹31 Cr₹61 Cr₹86 Cr₹48 Cr
———————
₹1163 Cr₹1097 Cr₹828 Cr₹793 Cr₹720 Cr₹645 Cr₹311 Cr
₹374 Cr₹302 Cr₹253 Cr₹200 Cr₹147 Cr₹99 Cr₹72 Cr
₹789 Cr₹795 Cr₹575 Cr₹593 Cr₹573 Cr₹546 Cr₹240 Cr
₹78 Cr₹50 Cr₹211 Cr₹173 Cr₹74 Cr₹18 Cr₹141 Cr
₹89 Cr₹19 Cr₹2 Cr₹12 L₹26 L₹37 L₹81 L
₹89 Cr₹19 Cr₹2 Cr₹12 L₹26 L₹37 L₹81 L
₹18 Cr₹12 Cr₹13 Cr₹12 Cr₹221 Cr₹141 Cr₹128 Cr
₹7 Cr₹23 Cr₹3 Cr₹9 Cr₹82 L₹45 L₹67 L
₹982 Cr₹899 Cr₹804 Cr₹786 Cr₹869 Cr₹706 Cr₹510 Cr
———————
₹402 Cr₹317 Cr₹244 Cr₹137 Cr₹73 Cr₹141 Cr₹198 Cr
₹326 Cr₹240 Cr₹208 Cr₹212 Cr₹195 Cr₹154 Cr₹111 Cr
₹460 Cr₹522 Cr₹350 Cr₹274 Cr₹232 Cr₹178 Cr₹184 Cr
₹14 Cr₹1 Cr₹47 Cr₹43 Cr₹89 Cr₹61 Cr₹3 Cr
₹18 Cr₹29 Cr₹27 Cr₹46 Cr₹33 Cr₹40 Cr₹14 Cr
₹30 Cr₹27 Cr₹21 Cr₹16 Cr₹10 Cr₹34 Cr₹29 Cr
₹1250 Cr₹1135 Cr₹896 Cr₹728 Cr₹633 Cr₹607 Cr₹539 Cr
₹1081 Cr₹951 Cr₹754 Cr₹536 Cr₹288 Cr₹371 Cr₹315 Cr
₹2232 Cr₹2034 Cr₹1701 Cr₹1514 Cr₹1502 Cr₹1313 Cr₹1049 Cr
₹193₹173₹146₹123₹1,160₹1,051₹810
₹193₹173₹146₹123₹105₹96₹74

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
₹345 Cr₹495 Cr₹413 Cr₹322 Cr₹238 Cr₹313 Cr₹213 Cr
₹37 Cr₹30 Cr₹37 Cr₹47 Cr₹53 Cr₹18 Cr₹12 Cr
-₹14 Cr-₹171 Cr-₹81 Cr-₹52 Cr-₹22 Cr-₹89 Cr-₹22 Cr
₹367 Cr₹354 Cr₹369 Cr₹316 Cr₹268 Cr₹242 Cr₹204 Cr
₹267 Cr₹245 Cr₹265 Cr₹246 Cr₹207 Cr₹167 Cr₹155 Cr
-₹143 Cr-₹160 Cr-₹155 Cr-₹158 Cr-₹112 Cr-₹195 Cr-₹113 Cr
-₹113 Cr-₹99 Cr-₹99 Cr-₹85 Cr-₹100 Cr₹31 Cr-₹43 Cr
₹11 Cr-₹14 Cr₹12 Cr₹3 Cr-₹4 Cr₹3 Cr-₹1 Cr
₹90 L₹15 Cr₹3 Cr₹67 L₹5 Cr₹2 Cr₹4 Cr
₹12 Cr₹90 L₹15 Cr₹3 Cr₹67 L₹5 Cr₹2 Cr

Fundamental Ratios

Consolidated
Standalone
Empty box

No results found

Share Price Live Stats

Open (₹)1,450.90
Volume (₹)69,958.00
High (₹)1,461.80
Upper Circuit1,733.70
Low (₹)1,435.00
Lower Circuit1,155.90
Prev Close1,444.80
52W High (₹)1,730.00
Price1,450.00
52W Low (₹)987.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)15090.40 Cr
Div. Yield (%)0.52
PE Ratio54.80
Debt to Equity0.00
Price to Book5.27
Book Value192.81
EPS (TTM)26.32
Face Value1.00
ROE (%)13.54

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
CONCORDBIONSE
LTP
1W Low
1W High
Market cap (₹)
1916-4 (-0.21%)
1905
1984.80
4,63,791Cr
9250+11 (0.12%)
9087
9467
2,45,081Cr
4905.5-144.5 (-2.86%)
4886.50
5066
1,90,351Cr
1143-48 (-4.03%)
1130.50
1187
1,14,833Cr
1394.7-28.8 (-2.02%)
1389.40
1426.10
1,14,163Cr
1868.5-70 (-3.61%)
1811.70
1949
1,00,660Cr
2132-39.5 (-1.82%)
2132
2192
98,431Cr
2368.8-14.1 (-0.59%)
2341.20
2419.20
98,305Cr
1155-23 (-1.95%)
1154.40
1179.90
96,906Cr
1637.3-8 (-0.49%)
1626.60
1717
95,300Cr
1450-31.1 (-2.10%)
1435
1504
15,090Cr

Concord Biotech Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹95.2Cr; with other income of ₹12.83Cr, profit before interest and tax came to ₹77.1Cr. Interest expense was ₹3.6Lakh; PBT before exceptional items stood at ₹77.07Cr. Cost mix (full year): raw materials ₹316.95Cr; employee cost ₹176.91Cr; depreciation ₹18.1Cr; other expenses ₹175.11Cr. Basis: consolidated annual results.

Concord Biotech Ltd Quaterly Results Key Takeaways

Concord Biotech Ltd reported ₹257.49Cr total income from operations in Jun 2026, softer than ₹326.08Cr in Mar 2026 but higher than ₹203.99Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹95.2Cr; with other income of ₹12.83Cr, profit before interest and tax came to ₹77.1Cr. Interest expense was ₹3.6Lakh, taking profit before tax to ₹77.07Cr. After tax of ₹20.65Cr, profit after tax stood at ₹56.42Cr (vs ₹88.64Cr in Mar 2026 and ₹42.57Cr in Jun 2025).